Drug Profile
BS HH 002
Alternative Names: BS-HH-002; BS-HH-002.SA; HH-002Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Hangzhou Bensheng Pharmaceutical
- Class Alkaloids; Antineoplastics; Harringtonines; Small molecules
- Mechanism of Action Activating transcription factor 3 inhibitors; Activating transcription factor inhibitors; Apoptosis stimulants; Janus kinase-2 inhibitors; Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Polycythaemia vera; Solid tumours
Most Recent Events
- 08 Feb 2021 Hangzhou Bensheng Pharmaceuticals and Shanghai Bensheng Pharmaceutical plans a phase I trial for Acute myeloid leukaemia (Recurrent,Refractory metastatic disease) and Myelodysplastic syndromes (Treatment-resistant) (SC) in February 2021 (NCT04743115)
- 28 Jun 2019 No recent reports of development identified for preclinical development in Polycythaemia-vera in USA
- 28 Jun 2019 No recent reports of development identified for preclinical development in Solid-tumours in USA